BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus. Rheumatology (Oxford) 2021:keab704. [PMID: 34528084 DOI: 10.1093/rheumatology/keab704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kedia N, Theillac V, Paez-escamilla M, Indermill C, Gallagher DS, Adam R, Qu-knafo AL, Amari F, Bottin C, Chotard G, Caillaux V, Strého M, Sedira N, Héron E, Becherel P, Bodaghi B, Mrejen-uretski S, Sahel A, Saadoun D, Errera M. The full range of ophthalmological clinical manifestations in systemic lupus erythematosus. Front Ophthalmol 2023;2. [DOI: 10.3389/fopht.2022.1055766] [Reference Citation Analysis]
2 Acharya C, Magnusson MO, Vajjah P, Oliver R, Zamacona M. Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus. J Clin Pharmacol 2022. [PMID: 36453450 DOI: 10.1002/jcph.2188] [Reference Citation Analysis]
3 Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol 2022;13:996662. [DOI: 10.3389/fimmu.2022.996662] [Reference Citation Analysis]
4 Gulko HE, Furie R; Division of Rheumatology, Northwell Health, Great Neck, NY, USA, Division of Rheumatology, Northwell Health, Great Neck, NY, USA. Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus. Rheumatology 2022;1:29. [DOI: 10.17925/rmd.2022.1.1.29] [Reference Citation Analysis]